Skip to main content
SpringerLink
Log in

Allogeneic Melanoma Lysate Vaccines

  • Chapter
Handbook of Cancer Vaccines

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Active specific immunotherapy, more commonly known as the use of “vaccines” for the treatment of cancer, has found its greatest use in melanoma. The ease of establishing primary cultures of melanoma cells, and cell lines, has enabled the study of immune responses toward melanoma more readily than most other tumors. The availability of these cell lines has facilitated the production of allogeneic vaccines for treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Old U. Cancer immunology: the search for specificity-G. H. A. Clowes Memorial lecture. Cancer Res 1981; 41:361–375.

    CAS  Google Scholar 

  2. Kan-Mitchell J, Imam A, Kempf RA, Taylor CR, Mitchell MS. Human monoclonal antibodies directed against melanoma tumor-associated antigens. Cancer Res 1986; 46:2490–2496.

    PubMed  CAS  Google Scholar 

  3. Kan-Mitchell J, Mitchell MS. Human monoclonal antibodies. Prog Clin Biol Res 1989; 288:85–94.

    PubMed  CAS  Google Scholar 

  4. Formenti SC, Mitchell MS, Taylor CR, Lipkin M, Jernstrom PH, Kan-Mitchell J. Reactivity of a human monoclonal antibody against carcinomas and other lesions of the colon. Cancer Immunol Immunother 1989; 28:296–300.

    Article  PubMed  CAS  Google Scholar 

  5. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643–1647.

    Article  PubMed  Google Scholar 

  6. Topalian SL, Hom SS, Kawakami Y, Mancini M, Schwartzentruber DJ, Zakut R, Rosenberg SA. Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes. J Immunother 1992; 12:203–206.

    Article  PubMed  CAS  Google Scholar 

  7. Berd D, Maguire HJ, Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984; 44:5439–5443.

    PubMed  CAS  Google Scholar 

  8. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine [published erratum appears in Ann Surg 1993; 217:309]. Ann Surg 1992; 216:463–482.

    CAS  Google Scholar 

  9. Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S. Increased effectiveness of interferon-alfa 2b following active specific immunotherapy for melanoma. J Clin Oncol 1994; 12:402–411.

    PubMed  CAS  Google Scholar 

  10. Elliott GT, McLeod RA, Perez J, Von Eschen KB. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Onc 1993; 9:264–272.

    CAS  Google Scholar 

  11. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002; 20:2058–2066.

    Article  PubMed  CAS  Google Scholar 

  12. Hersey P. Vaccinia viral lysates in treatment of melanoma. In: Mitchell MS, ed. Biological approaches to cancer treatment: biomodulation. New York: McGraw-Hill, 1992:302–325.

    Google Scholar 

  13. Kirkwood JM, Ernstoff ME. Potential applications of the interferons in oncology. Semin Oncol 1986; 13:48–56.

    PubMed  CAS  Google Scholar 

  14. Vaishampayan U, Abrams J, Darrah D, Jones V, Mitchell MS. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res 2002; 8:3696–3701.

    PubMed  CAS  Google Scholar 

  15. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998; 25:623–635.

    PubMed  CAS  Google Scholar 

  16. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S. Active specific immunotherapy of melanoma. Phase I trial of allogeneic melanoma lysates and a novel adjuvant. Cancer Res 1988; 48: 5883–5893.

    PubMed  CAS  Google Scholar 

  17. Mitchell MS, Harel W, Kempf RA, Kan-Mitchell J, Boswell WD, Hu E, Dean G, Stevenson L. Activespecific immunotherapy for melanoma. J Clin Oncol 1990; 8:856–869.

    PubMed  CAS  Google Scholar 

  18. del Guercio MF, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, Sette A. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 1995; 154: 685–693.

    PubMed  Google Scholar 

  19. LeMay LG, Kan-Mitchell J, Goedegebuure P, Harel W, Mitchell MS. Detection of human melanomareactive CD4+ HLA class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma. Cancer Immunol Immunother 1993; 37:187–194.

    Article  PubMed  CAS  Google Scholar 

  20. Mitchell MS, Harel W, Groshen S. Association of HLA phenotype with clinical response to active specific immunotherapy of melanoma. J Clin Oncol 1992; 10:1158–1168.

    PubMed  CAS  Google Scholar 

  21. Sosman JA, Unger JM, Liu PY, Flaherty LE , Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine:impact of HLA class I antigen expression on outcome. J Clin Oncol 2002; 20:2067–2075.

    Article  PubMed  CAS  Google Scholar 

  22. Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S. MHC antigens in human melanomas. Semin Cancer Biol 1991; 2:35–45.

    PubMed  CAS  Google Scholar 

  23. Mitchell MS, Harel W, Kan-Mitchell J, LeMay LG, Goedegebuure P, Huang X-Q, Hofman F, Groshen S. Active specific immunotherapy of melanoma with allogeneic cell lysates: rationale, results and possible mechanisms of action. In: Bystryn J-C, Ferrone S, Livingston P, eds. Specific immunotherapy of cancer with vaccines. Ann N Y Acad Sci 1993; 690:153–166.

    Google Scholar 

  24. Murray DR, Cassel WA, Torbin AH, Olkowski ZL, Moore ME. Viral oncolysate in the management of malignant melanoma. II. Clinical studies. Cancer 1977; 40:680–686.

    Article  PubMed  CAS  Google Scholar 

  25. Wallack M, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998; 187:69–77.

    Article  PubMed  CAS  Google Scholar 

  26. Chan AD and Morton DL. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol 1998; 25:611–622.

    PubMed  CAS  Google Scholar 

  27. Mitchell MS, Kan-Mitchell J, Morrow PR, Darrah D, Jones VE, Mescher MF. Phase I trial of large multivalent immunogen (LMI) derived from melanoma lysates, in patients with disseminated melanoma. Submitted for publication, 2003.

    Google Scholar 

Download references

Authors
  1. Malcolm S. Mitchell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Duke University Medical Center, Durham, NC, USA

    Michael A. Morse MD , Timothy M. Clay PhD  & H. Kim Lyerly MD ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Humana Press Inc.

About this chapter

Cite this chapter

Mitchell, M.S. (2004). Allogeneic Melanoma Lysate Vaccines. In: Morse, M.A., Clay, T.M., Lyerly, H.K. (eds) Handbook of Cancer Vaccines. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-680-5_26

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-680-5_26

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9818-9

  • Online ISBN: 978-1-59259-680-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation